These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 25674880)

  • 1. Incidental Acinic Cell Carcinoma of the Parotid Gland Discordant on 123I-MIBG, 111In-Octreotide, and 18F-FDG PET/CT in a Patient With Neuroendocrine Tumor of the Cecum.
    Makis W; McCann K; McEwan AJ
    Clin Nucl Med; 2015 Aug; 40(8):676-8. PubMed ID: 25674880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET.
    Binderup T; Knigge U; Loft A; Mortensen J; Pfeifer A; Federspiel B; Hansen CP; Højgaard L; Kjaer A
    J Nucl Med; 2010 May; 51(5):704-12. PubMed ID: 20395333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-FDG PET/CT in a 16-year-old patient with hydranencephaly.
    Short RG; Kardan A
    Clin Nucl Med; 2014 Oct; 39(10):e445-7. PubMed ID: 24395017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parotid gland metastasis from squamous cell carcinoma of esophagus detected by FDG PET/CT.
    Hsieh TC; Wu YC; Sun SS; Yang CF; Kao CH
    Clin Nucl Med; 2012 Oct; 37(10):1001-2. PubMed ID: 22955076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional imaging of malignant paragangliomas and carcinoid tumours.
    Le Rest C; Bomanji JB; Costa DC; Townsend CE; Visvikis D; Ell PJ
    Eur J Nucl Med; 2001 Apr; 28(4):478-82. PubMed ID: 11357498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
    Jois B; Asopa R; Basu S
    Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type.
    Balogova S; Talbot JN; Nataf V; Michaud L; Huchet V; Kerrou K; Montravers F
    Eur J Nucl Med Mol Imaging; 2013 Jun; 40(6):943-66. PubMed ID: 23417499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.
    Nilica B; Waitz D; Stevanovic V; Uprimny C; Kendler D; Buxbaum S; Warwitz B; Gerardo L; Henninger B; Virgolini I; Rodrigues M
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1585-92. PubMed ID: 26922350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.
    Kulkarni HR; Baum RP
    PET Clin; 2014 Jan; 9(1):83-90. PubMed ID: 25029937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential for Increasing Uptake of Radiolabeled
    Pollard JH; Menda Y; Zamba KD; Madsen M; O'Dorisio MS; O'Dorisio T; Bushnell D
    Cancer Biother Radiopharm; 2021 Oct; 36(8):632-641. PubMed ID: 34252288
    [No Abstract]   [Full Text] [Related]  

  • 12. Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma.
    De Luca S; Fonti R; Camera L; Salvatore B; Faggiano A; Ciarmiello A; Segreto S; Colao A; Salvatore M; Del Vecchio S
    Ann Nucl Med; 2016 Apr; 30(3):234-41. PubMed ID: 26753628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravascular small cell neuroendocrine tumor in the neck.
    Chang CA; Jong I; Nowicki A; Ramdave S
    Clin Nucl Med; 2014 Nov; 39(11):988-9. PubMed ID: 24978335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of parotid gland incidentalomas on (18)F-FDG PET/CT.
    Makis W; Ciarallo A; Gotra A
    Clin Imaging; 2015; 39(4):667-71. PubMed ID: 25888252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple Neoplasms Simultaneously Diagnosed by Complementary Triple-Tracer PET/CT and 123I-MIBG Scintigraphy.
    Søndergaard E; Ebbehoj A; Poulsen PL; Gormsen LC
    Clin Nucl Med; 2017 Jan; 42(1):e61-e66. PubMed ID: 27824319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined imaging with 18F-FDG-PET/CT and 111In-labeled octreotide SPECT for evaluation of thymic epithelial tumors.
    De Luca S; Fonti R; Palmieri G; Federico P; Del Prete G; Pacelli R; Pace L; De Placido S; Salvatore M; Del Vecchio S
    Clin Nucl Med; 2013 May; 38(5):354-8. PubMed ID: 23486323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of 99mTc-HYNIC-TOC and 18F-FDG PET/CT in the evaluation of duodenal neuroendocrine tumor with atypical and extensive metastasis responding dramatically to a single fraction of PRRT with 177Lu-DOTATATE.
    Basu S; Abhyankar A
    J Nucl Med Technol; 2014 Dec; 42(4):296-8. PubMed ID: 25190735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
    Kaltsas G; Korbonits M; Heintz E; Mukherjee JJ; Jenkins PJ; Chew SL; Reznek R; Monson JP; Besser GM; Foley R; Britton KE; Grossman AB
    J Clin Endocrinol Metab; 2001 Feb; 86(2):895-902. PubMed ID: 11158063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple Pathologies Seen on a Single Contrast-Enhanced 18F-FDG PET/CT: Reiteration of Lessons Previously Learned.
    Sharma P; Marangmei C
    Clin Nucl Med; 2015 Sep; 40(9):750-1. PubMed ID: 25706797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis.
    Papathanasiou ND; Gaze MN; Sullivan K; Aldridge M; Waddington W; Almuhaideb A; Bomanji JB
    J Nucl Med; 2011 Apr; 52(4):519-25. PubMed ID: 21421719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.